Safety and Tolerability of opicapone in Parkinson’s disease
Objective: To evaluate safety and tolerability of opicapone as an add‐on treatment to levodopa in Parkinson's disease (PD) patients. Background: Opicapone is a recently approved…Role of microRNA-153 and -223 in Parkinson disease
Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…Pattern and Presentation of Parkinson Disease in two Teaching Hospitals in Enugu, South East Nigeria
Objective: To describe the pattern of presentation of Parkinson disease in patients attending medical out-patient clinic in Enugu South East Nigeria. Background: Parkinson Disease is…Exosomes from patients with Parkinson’s disease are pathological in mice
Objective: To verify the hypothesis that serum-derived exosomes from patients with Parkinson’s disease (PD) may serve as risk carriers for inter-neuronal risk transmission, eventually resulting…Applicability of modified definition of Vascular Parkinsonism in patients with Parkinsonism attending outpatient department: A tertiary care hospital-based study in south India
Objective: This study aims to assess the applicability of modified Vascular Parkinsonism (VP) criteria in outpatient department in a tertiary care hospital in south India.…123I-FP-CIT SPECT imaging in early PD patients versus mid and late onset PD: Longitudinal data from the PPMI study
Objective: To determine whether there are longitudinal differences in dopaminergic denervation [as exemplified by signal reduction in 123I-FP-CIT SPECT] in early PD patients versus mid…Case-control study of risk developing parkinsonism in Alzheimer’s disease in relation to hypertension, dyslipidemia, and diabetes in Taiwan
Objective: To clarify the relationship between vascular risk factors and parkinsonism in Alzheimer’s disease Background: This case-control study investigated the associations of a history of…Memantine and 3D gait analysis in patient with Parkinson’s disease: an observer-blind randomized clinical trial
Objective: To examine the efficacy of memantine (20 mg), a non-competitive NMDAR antagonist, in the treatment of gait impairment in PD patients with mild cognitive…Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA
Objective: To report a patient with MSA with concomitant occurrence of TDP-43-labeled and a-synuclein labeled inclusions in oligodendrocytes. Background: The pathologic hallmark in multiple system atrophy…The Progressive Supranuclear Palsy Functional Disability Scale: Sensitivity to change
Objective: To determine the sensitivity to change within 12 months as well as completion time of the Progressive Supranuclear Palsy Functional Disability Scale (PSPFDS). Background:…
- « Previous Page
- 1
- …
- 167
- 168
- 169
- 170
- 171
- …
- 405
- Next Page »